Transcriptional profiling indicated that CD64hiSiglecF−MHC-II−Lyve1+ macrophages from CSF-1–Fc-treated, LPS-challenged, hypoxic mice had lower expression of archetypal inflammatory genes (Il1b, Il6, Tnf and Il18 and S100a11) and genes associated with lung fibrosis (Mmp8, Mmp12, Col14a1, Fpr1, Pdgfa and Pdgfb) relative to CD64hiSiglecF−MHC-II− from PBS-treated counterparts. This evidence concerns the gene CSF1 and pulmonary fibrosis.